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ABSTRACT 
The aim of the present investigation was to formulate and evaluate solid self-micro emulsifying drug-delivery systems (S-SMEDDS) to improve 
solubility and dissolution profile of Linagliptin. Solubility of Linagliptin in different oils, surfactants and co-surfactants was assessed and 
optimizations of pseudo-ternary plots were also carried out for preparation of liquid SMEDDS. D-optimal design mixture was used in the 
optimization of Linagliptin loaded liquid SMEEDS. The optimized SMEEDS were characterized for globule size, zeta potential, dilution stability, 
transmittance, pH and in-vitro release profile. The morphology of the Linagliptin SMEEDS was observed by Transmission Electron Microscopy 
(TEM). Among the different silicates, Nusillin US2 was used as the solid carrier/absorbent to formulate S-SMEEDS of Linagliptin. Improved in-
vitro dissolution profile of optimized formulation was observed, resulting in multifold improvement in the absorption profile of Linagliptin as 
compared with pure drug. In a nutshell, this optimized S-SMEDD formulation holds great promise for enhancement of its physiochemical and 
biological attributes. 
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1. INTRODUCTION 
Linagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, widely 
used in the treatment of diabetes mellitus type 2. Though, 
low aqueous solubility and poor permeation profile of 
Linagliptin results in the low bioavailability (~30%) [1, 2]. To 
date, several formulation approaches such as Solid 
Dispersions [3], polymeric nanofibers for transmucosal 
delivery [4], and non-ionic surfactant vesicles [5] have been 
investigated to overcome the low aqueous solubility and 
poor permeation profile and thereby improving the 
bioavailability of Linagliptin. In recent decades, Self-
manoemulsifying drug-delivery systems (SMEDDS) have 
emerged as an effective drug delivery system due to their 
proven ability to enhance aqueous solubility, permeation 
and bioavailability of lipophilic drugs [6]. SMEDDS can be 
defined as the isotropic mixture of the drug, oil, surfactant, 
and co-surfactant that form a spontaneous oil-in-water 
(O/W) microemulsion when introduced into an aqueous 
medium under gentle agitation [7]. Having potential 
advantages such as thermodynamic stable, globule size 
around 100 nm, ability to present the drug in solubilized 
form into the gastrointestinal tract (GIT) offers grater 
interfacial area for absorption of drug and also provides 
chemical and enzymatic stability, increased lymphatic 
transport along with inhibition of P-glycoprotein mediated 
drug efflux [8, 9]. 
Excipients used in SMEDDS and their concentrations have 
profound effect on the globule size of the microemulsion 
which may ultimately affect its in-vitro and in-vivo 
performance [10]. Though, such delivery systems often 
developed and optimized by a trial-and-error tactic by 
varying one factor at a time and keeping all other factors 
constant. This univariate approach is time-consuming and 
requires a larger number of experiments to describe the 
effect of excipients (oil, surfactant and co-surfactant) on the 
physical properties of the SMEDDS and frequently fails to 
project the true optimal composition because interactions 
between factors were not considered [11]. To understand the 
multi-factorial relationship between formulation factors and 
product desirability generally requires the multivariate 
approach, such as Design of Experiment (DOE) [12]. 
Optimization of formulation by using DOE offers few 
experimental runs and explain the synergism or interaction 
among the factors which may ultimately leads to yield a 
Patel et al                                                                                                                        Journal of Drug Delivery & Therapeutics. 2019; 9(2):47-56 
ISSN: 2250-1177                                                                                  [48]                                                                                 CODEN (USA): JDDTAO 
robust product with several advantages such as time, money 
and efforts, etc. [6]. 
In addition, it is worthy to develop solid SMEDDS dosage 
form due to its better stability, simple and cost-effective 
development, transportability and enhanced therapeutic 
success due to improved patient compliance [13]. Therefore, 
the present investigation was aimed to develop solid 
SMEDDS of Linagliptin and optimized by using D-optimal 
design mixture. The formation of a microemulsion may offer 
a large interfacial surface for better drug solubilization 
which may leads to an improved solubility and dissolution 
profile of Linagliptin. 
2. MATERIALS AND METHODOLOGY  
Linagliptin was obtained as the gift sample form Alembic 
Pharmaceuticals Ltd., Vadodara, Gujarat, India. Oleic acid, 
Corn oil, sunflower oil and castor oil were acquired from 
Triveni Interchem Pvt Ltd., India. Olive oil, cottonseed oil, 
linseed oil, and Propylene Glycol (PG) were purchased from 
S.D. Fine Chemicals, India. Acconon CC 6, Acconon C 80, 
Capmul MCM and Caprol MPGO were bought from Abitec 
Corporation, USA. Isopropyl Myristate was purchased from 
Haxon Laboratory Pvt. Ltd., India. Labrasol, Transcutol HP, 
Lauroglycol FCC and Lauroglycol 90 were obtained as gift 
sample from Gattefosse, India. Span 20, Tween 20, Tween 80, 
Poly Ethylene Glycol (PEG - 200, 400 and 600), Acetonitrile 
and Methanol (Analytical and HPLC Grades) were obtained 
from Spectrochem, India. Cremophor RH 40 was procured 
from BASF, India. All other chemicals used were of analytical 
grade (AR).  
2.1 Screening of formulation excipients based on 
saturation solubility study 
Solubility of Linagliptin was analyzed in various excipients 
i.e. oils, surfactants and co-surfactants to evaluate the 
maximum drug loading efficacy. An excess amount of 
Linagliptin in each different excipient was added into the 
centrifuge tubes and subjected to mechanical shaking for 24 
h at 50 strokes/min. Each tube was then centrifuged at 5000 
rpm for 10 min to separate the excess insoluble drug (at 
bottom) and the supernatant was isolated and filtered [14]. 
The concentration of Linagliptin in the filtrate was 
determined by UV spectrophotometry at λmax of 228 nm with 
suitable dilutions.   
2.2 Constructions of Pseudo Ternary Phase Diagram 
Water titration method was used to construct the ternary 
phase diagram between oils, water and Smix (mixture of 
surfactant and cosurfactant). The weight ratio of Smix was 
varied as 1:1, 2:1 and 3:1 and the oil was added to this Smix in 
10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9 ratio with 
continuous stirring. To this mixture, water was added as 
drop wise until the turbidity/haziness was observed. Among 
these, clear/dispersion with slight bluish tint were 
considered as the microemulsion region and the pseudo 
ternary phase diagram was plotted by using Chemix 
Software to select optimum Smix ratio.  
2.3 Formulation Development and Optimization of 
Linagliptin SMEDDS by using D-optimal Design 
D-optimal mixture design was used as a statistical tool to 
understand the relationship between formulation variables 
and response parameters. Respective levels of the 
independent variables were selected on the basis of 
preliminary optimization of the SMEDDS components. Table 
1 enlists the independent variables and response parameters 
with their respective constraints. For the fabrication of 
Linagliptin loaded SMEDDS, 10 mg accurately weighed 
Linagliptin was dissolved in predetermined concentrations 
of Oil and Smix as suggested by the design. All the excipients 
were homogeneously mixed by vortexing to get uniform, 
transparent and clear SMEDDS. The physiochemical 
characterization of the optimized SMEDDS of Linagliptin 
were carried for critical quality attributes (CQAs). 
  
Table-1: List of Independent variables and response parameters 
Independent Variables Low Value High Value 
Oil (%) (X1) 5 15 
Surfactant (%) (X2) 55 65 
Co-surfactant (%) (X3) 25 30 
Responses Parameters 
Globule size (nm) (Y1) 
Transmittance (%) (Y2) 
 
Globule size (Y1) and Zeta Potential   
Globule size, PDI and Zeta potential of Linagliptin loaded 
SMEDDS were measured by ZetaSizer Nano ZS (Malvern 
Instruments, United Kingdom). In brief, 0.5 g of SMEDDS 
were emulsified in the 250 ml phosphate buffer (PBS) pH 6.8 
and allowed to stabilize. Resulting microemulsions were 
filled in the clear disposable cuvettes and the globule size, 
PDI and zeta potential were measured and recorded (n=3).   
2.3.1 % Transmittance (Y2) 
% Transmittance of Linagliptin loaded SMEDDS was 
analyzed at λmax 650 nm by UV-visible spectrophotometry 
(UV1800, Shimadzu, Japan). In brief, 0.5 g of SMEDDS were 
emulsified in the 250 ml phosphate buffer (PBS) pH 6.8 and 
allowed to stabilize. Phosphate buffer pH 6.8 used as blank to 
determine the % transmittance. 
 
2.3.2 Overlay plot and check point batch analysis 
Design Expert 7.0.0 (Stat-Ease) software was used to 
understand the effect of independent variables on response 
parameters. 3D response surface plots and desirability plot 
were generated through software to understand the effect of 
each component i.e. oil, surfactant and co-surfactant on the 
response parameters i.e. globule size and % transmittance.   
2.4 Screening of solid adsorbent and preparation of 
Solid-SMEDDS 
Micro Crystalline Cellulose (MCC 102), Aeroperl® 300, 
Aerosil® 200, and Neusilin® US2 were selected and screened 
for their adsorption capacity. In brief, 1 ml of Linagliptin 
loaded SMEDDS and solid adsorbent homogenously mixed in 
the glass pestle. The amount of solid adsorbent was added in 
the increments of 50 mg until the blend displayed free 
flowing properties. Final selection of the solid adsorbent was 
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based on the minimum quantity required to exhibit free 
flowing characteristics of the blend. Flow characteristics of 
the optimized S-SMEDDS of Linagliptin were measured i.e. 
Angle of Repose, Hausner’s ratio and Carr’s index [15]. 
2.5 Physicochemical characterization of Linagliptin 
loaded SMEDDS/Solid-SMEDDS 
2.5.1 Self-emulsification time 
The time of self-emulsification of optimized Linagliptin 
loaded SMEDDS was evaluated using USP type II dissolution 
apparatus. 0.5 g of SMEDDS was emulsified 250 ml of 
phosphate buffer (pH 6.8) in 500ml vessels of dissolution 
apparatus and the temperature was maintained at 37 ± 1°C 
with paddle rotating at 50 rpm. Time required to obtain clear 
and transparent phase was considered as the self-
emulsification time. 
2.5.2 Thermodynamic Stability 
The optimized SMEDDS of Linagliptin were subjected to 
thermodynamic stability testing i.e. heating cooling cycle, 
centrifugation test and freeze thaw cycle.  SMEDDS was 
tested at 3 heating (40˚C) cooling (4˚C) cycles with 48 h 
storage at each temperature. The formulation was then 
assessed for centrifugation test at 4000 rpm for 30 min. 
Moreover, freeze thaw stress testing of the formulation was 
also carried out by freezing the SMEDDS at -20˚C and -70 ˚C 
and thawing at 25 ˚C with 48 h of storage at each 
temperature conditions. All the formulations were evaluated 
for phase separation, turbidity or any kind of instability.    
2.5.3 Cloud point measurement  
For the determination of cloud point of formulation, 0.5 g of 
SMEDDS was dispersed in 250ml of phosphate buffer pH 6.8 
and allowed to stabilize. The dispersion was then subjected 
to heating under water bath with gradually increase in 
temperature. The temperature at which the turbidity was 
observed was considered as cloud point.  
2.5.4 Transmission Electron Microscopy (TEM)  
0.5 g of Solid SMEEDS of Linagliptin was emulsified in the 
250 ml phosphate buffer pH 6.8 and allowed for stabilization 
for an hour. The resultant dispersion was then filtered 
through nylon membrane filter (0.45 μ, Whatman®) in order 
to separate adsorbent particles and subjected for TEM (JEM-
1200, Joel, Japan) analysis. In brief, 5 μl of sample was placed 
on the copper grid (3mm, 300 mesh), excess of sample was 
removed through blotting paper. The grid was then air dried 
and observed with 100kv acceleration voltage under TEM.  
2.5.5 Assay 
Drug content of Linagliptin was estimated in the developed 
formulation of SMEDDS. 0.5g accurately weighed SMEDDS 
was transferred to 50ml methanol to dissolve Linagliptin and 
filtered through nylon membrane filter (0.22 μ, Whatman®). 
The concentration of Linagliptin in the filtrate was 
determined by UV spectrophotometry at λmax of 228 nm with 
suitable dilutions. Estimation was performed in triplicate 
and results are expressed as mean ± SD.  
 
 
 
2.5.6 In-vitro drug release study 
In vitro drug release study of Linagliptin loaded Solid-
SMEDDS was performed by using dialysis bag technique [16, 
17]. 0.5 g of Solid-SMEDDS were incorporated in the pre-
activated dialysis membrane (12kD molecular weight, Hi 
Media Laboratories Pvt. Ltd.) and both the ends were sealed 
with clamp and submerged in 250 ml phosphate buffer (pH 
6.8) at 50 rpm having temperature of 37 ± 0.5 °C. At 
predetermined time intervals i.e. 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 
h, 5 ml sample was withdrawn and replenished with same 
volume of fresh medium. The in-vitro release profile of 
Linagliptin from the solid-SMEDDS was compared with the 
suspension of Linagliptin. The concentration of Linagliptin 
was determined by UV spectrophotometry at λmax of 228 nm 
with suitable dilutions. Estimation was performed in 
triplicate and results are expressed as mean ± SD. The drug 
release mechanism was studied by plotting various release 
kinetic models. 
2.5.7 Stability study 
Stability study of optimized solid-SMEDDS of Linagliptin was 
conducted for three months as per the ICH guidelines as 
described in the stability testing of new drug substances and 
drug products [18]. This study was carried out at room 
temperature and accelerated conditions i.e. at 45 ± 2°C (75 ± 
5% RH) for 3 months and analyzed for drug content, globule 
size and physical appearance at time intervals of 0,15,30,60 
and 90 days.   
3. RESULTS AND DISCUSSION 
3.1.1 Screening of formulation excipients based on 
saturation solubility study 
Oil is an important excipient in the formulation of SMEDDS, 
which increases the solubility and fraction of the lipophilic 
drugs transported via intestinal lymphatic system, therefore 
by increasing its absorption through gastro-intestinal tract 
[19]. In addition, high solubility of a lipophilic drug in oil 
phase is noteworthy assessment because it requires lesser 
amount of oil to form the microemulsion preconcentrates 
[20]. Linagliptin exhibited highest solubility 65±4.1 mg/ml in 
Capmul MCM among the various oils screened.  
Similarly, surfactant also plays critical role by forming thin 
film at the interface and helps in decreasing the globule size 
and stabilization of emulsion and uses their absorption 
enhancing activity by partitioning into the cell membrane 
and disrupt the structural organization of lipid bilayers 
results in increase in permeation of drugs [19]. Linagliptin 
exhibited highest solubility in Labrasol 58±3.2 mg among the 
different surfactant screened. 
Moreover, co-surfactant also helps by penetrating into the 
interface and form void spaces for the penetration of water 
and thereby increasing the interfacial fluidity which enables 
the spontaneous formation of emulsion [21]. Linagliptin 
exhibited highest solubility in Transcutol HP 42±1.3 mg 
among the different co-surfactant screened. Thus, based on 
the solubilization potential for Linagliptin, oil phases 
(Capmul MCM), surfactants (Labrasol) and co-surfactant 
(Transcutol HP) were selected and examined for their 
optimized weight ratios by using ternary phase diagram. The 
saturation solubility profile of Linagliptin in oils, surfactants 
and co-surfactants was find out and represented in Figure 1. 
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Figure 1: Saturation solubility profile of Linagliptin 
 
3.1.2 Pseudo ternary phase diagram 
Ternary phase diagram constructed of the blank SMEDDS to 
find the microemulsion region. weight ratio of Smix 
(Labrasol:Transcutol HP) was varied as 2:1, 3:1 and 3:2 and 
plotted (Figure 2) by using Chemix software as the batches of 
1:1 and 1:2 Smix ratio were precipitated on dilution with 
water. Moreover, oil to Smix ratio (2:1) of 1:9 and 2:8 
proportions in water titrations were showed clear and 
transparent solution up to infinite dilutions with water. 
Thus, Smix ratio of 2:1 was selected for further optimization.
    
   
Figure 2: Ternary phase diagram constructed of the blank SMEDDS 
 
Figure-3: Ternary Phase Diagram of Linagliptin loaded SMEDDS 
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3.1.3 Optimization of Linagliptin SMEDDS by using D-
optimal Mixture Design 
The Linagliptin loded SMEDDS was further optimized by D-
optimal mixture design using Stat-Ease Deign Expert 
Software (7.0.0). This design was selected to study the 
quadratic effects, interactions and optimization of SMEDDS 
in order to achieve the optimum desirability. Based on the 
results of the preformulation studies, the low-high limits of 
each variables i.e. Oil, surfactant and co-surfactant (Table 1) 
were set in design of experiment and the response 
parameters were recorded (Table 2). Globule size and % 
transmittance were found in the range of 52.1±2.1 to 
310.1±10.2 nm and 69.5±0.7 to 99.6±0.3 respectively. In 
order to investigate the significance level and to validate the 
design model, analysis of variance (ANOVA) was performed. 
It may justify the effects of each independent components on 
the response parameters i.e. globule size and % 
transmittance. The results are showed in Table 3. From the 
results, F value of both of the response parameters suggests 
the significance of the selected mathematical model. In 
addition, p-value at 99% (p<0.001) confidence intervals 
suggests that the model was highly significance among the 
observed and standard means and was best fitted for the 
present study. 
 
Table 2: Experimental batches of Linagliptin loaded SMEDDS and their outcomes as per D-optimal mixture design 
Values are represented as mean ± SD (n=3). 
Table 3: Analysis of variance (ANOVA) for statistical analysis of desired response parameters 
Response ANOVA analysis of desired response parameters  
Source Sum of 
squares 
D.F. Mean 
square 
F value p value  
 
Inference 
Globule Size (nm) Model 88317.49 5 17663.50 158.73 < 0.0001 Significant 
 Linear 
Mixture 
79642.32 2 39821.16 357.84 < 0.0001 Significant 
 Residual 1112.82 10 111.28    
 Lack of fit 812.78 5 162.56 2.71 0.1491 Not 
Significant 
 Pure error 300.05 5 60.01    
 Cumulative 
total 
89430.31 15     
% Transmittance Model 1302.82 5 260.56 162.08 < 0.0001 Significant 
 Linear 
Mixture 
1237.22 2 618.61 384.79 < 0.0001 Significant 
 Residual 16.08 10 1.61    
 Lack of fit 11.69 5 2.34 2.67 0.1528 Not 
Significant 
 Pure error 4.38 5 0.88    
 Cumulative 
total 
1318.90 15     
 
 
3.1.3.1 Effect of independent variables on globule 
size(Y1)  
Globule size analysis generally regarded as critical factor in 
the formation of microemulsion preconcentrates as the 
nano-sized globules have been known to have pronounced 
rate and extent of absorption through the GIT [22]. As it can 
see from Figure-4, as concentration of oil (Capmul MCM) 
increases, the globule size increases linearly and vice versa 
i.e. globule size decreases with an increase in concentration 
of surfactant and co-surfactant. It is clearly observed from 
the slope and from curve of the surface plot, that surfactant 
alone is not enough to decrease the globule size in nano-
sized range, concentration of co-surfactant is also 
responsible for the decrease in the globule size. The 
Runs Oil (%) Surfactant (%) Co-surfactant (%) Globule Size (nm) % Transmittance 
1 12.516 60.00 27.484 221.5±9.8 82.5±0.5 
2 9.728 60.272 30.00 123.2±6.1 92.4±0.4 
3 10.803 60.913 28.284 134.2±4.1 87.5±0.6 
4 7.491 62.555 29.955 68.5±2.1 97.7±0.5 
5 11.648 61.712 26.640 138.7±3.4 82.8±0.7 
6 9.988 65.00 25.012 112.3±3.7 91.4±0.6 
7 5.499 65.00 29.501 52.1±2.1 99.5±0.4 
8 9.988 65.00 25.012 116.7±2.8 90.8±0.8 
9 14.793 60.207 25.00 310.1±10.2 69.5±0.7 
10 9.958 62.622 27.420 120.1±3.3 91.7±0.5 
11 7.764 64.963 27.273 81.7±2.9 97.4±0.6 
12 5.499 65.00 29.501 58.7±2.1 99.6±0.3 
13 7.491 62.555 29.955 65.4±3.2 98.5±0.4 
14 12.396 62.604 25.00 178.5±8.7 80.2±0.8 
15 9.728 60.272 30.00 129.8±6.5 91.4±0.7 
16 14.793 60.207 25.00 288.1±12.3 72.1±0.9 
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increased concentration of surfactant at oil interfaces often 
results in the disruption of transient interfacial tension and 
reduction in globule size, indicates that the globule size is 
inversely proportional to the surfactant concentration in the 
formulation [23]. As shown in equation 1, X1, X2 and X3 
(interaction terms) depicting that synergism and weight 
ratio of selected components significantly decreased the 
globule size. Moreover, from the polynomial results, the 
magnitude of combined interaction (X1X2, X2X3 and X1X3) 
was considerably higher as compared to their individual 
variables.
 
Globule Size (nm) = + 323.68 * A - 1454.17  * B - 545.51 * C + 2719.39 * A * B + 1048.00 * A * C + 4153.44 * B * C - 5727.55 * A 
* B * C - 2219.90 * A * B * (A-B) - 865.29 * A * C * (A-C) + 1518.71 * B * C * (B-C) …………..……….…………………………..…………..…Eq. (1) 
Where, A=X1= Oil, B=X2=Surfactant, C=X3=Co-surfactant. 
  
Figure 4: 2D and 3D response surface plots of facters affecting globule size 
 
3.1.3.2 Effect of independent variables on % 
transmittance (Y2) 
% Transmittance is also an critical and fundamental 
attribute in the formulation of SMEDDS as it represents the 
optical birefringence and homogenecity of the formulation. 
As shown in the equation no. 2, oil component (A) has a 
negative coefficient value indicates the decrease in optical 
clarity while components B (surfactant) and C (co-
surfactant) having positive effect on the dependent 
parameters and suggests the increased optical clarity of the 
formulation.
   
 
% Transmittance = -17.41384  
* A + 2.71673 * B + 7.00247 * C + 0.13604  * A* B + 0.21935 * A * C - 0.14149 * B * C …………………..…Eq. (2) 
Where, A=X1= Oil, B=X2=Surfactant, C=X3=Co-surfactant. 
 
Moreover, as it can see form Figure-5 (2D and 3D response 
surface plots), as the concentration of oil increases the % 
transmittance decreases in linear manner. While synergistic 
effect was observed in the case of increase in the 
concentration of surfactant and co-surfactant. The maximum 
transparency was found to be 99.6±0.3 among all the design 
batches. This study was further supported by the previous 
research work done on the selection of % transmittance as 
critical factor in the formulation of SMEDDS [23]. 
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Figure 5: 2D and 3D response surface plots of facters affecting % transmittance 
 
3.1.3.3 Overlay plot and check point batch analysis 
Overlay plot was created by superimposing contour plots of 
response parameters (Y1 and Y2) by the design expert 
software. This plot demonstrates the area of desired 
response values in the factor space also called desirability 
plots (Figure-6). This plot also demonstrates the low and 
high desirability areas of the responses obtained by using 
different combinations of the independent variables. 
Moreover, the predicted and experimental values of the 
check point batch suggested by the software are shown in 
table 4. This impiles that this D-optimal mixture design was 
suitable to design robust formulation with high 
reproducibility. 
 
     
Figure 6: Overlay and desirbility plots 
Table 4:  Values of independent variables of optimized SMEDDS formulation of Linagliptin 
Linagliptin loaded SMEDDS 
Independent Variables 
 Oil (A) 5.49 
 Surfactant (B) 65.00 
 Co-surfactant (C) 29.50 
Response parameters 
Globule size (Y1) (nm) Predicted 55.098  
 Experimental 52.8±1.8 
% Transmittance (Y2) (%) Predicted 99.8 
 Experimental 99.7±0.3 
Values are represented as mean ± SD (n=3). 
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3.1.4 Selection of solid adsorbent  
The minimum quantties of selected solid adsorbents i.e. 
Aerosil® 200, Aerosil® 300, and Neusilin® US2 required to get 
free flowing powder blend for Linagliptin SMEDDS were 600, 
550 and 400 mg respectively to adsorb 1 ml of liquid 
SMEDDS, while in the case of Micro Crystalline Cellulose 
(MCC 102), no adsorption of the SMEDDS was found. 
Neusilin® US2 was selected as solid adsorbent amongst the 
screened silicates derivatives due to its highly porous nature 
coupled with good flow characteristics. Moreover, table 5 
shows the micromeritic properties of the solid-SMEDDS of 
linagliptin. It depicts that the solid-SMEDDS of Linagliptin 
exhibited excellent flow characteristics. 
 
Table 5: Micromeritic properties of solid-SMEDDS of Linagliptin  
Powder flow characteristics Results Inference 
Bulk density (gm/ml) 0.427 ± 0.005 - 
Tapped density (gm/ml) 0.449 ± 0.06 - 
Angle of repose 29.87 ± 1.21 Very Good 
Hausner’s ratio 1.12 ± 0.004 Excellent 
Carr’s index 9.91 ± 0.007 Excellent 
Values are represented as mean ± SD (n=3). 
 
3.1.5 Characterization of the optimized SMEDDS of 
Linagliptin  
3.1.5.1 Self-emulsification time and zeta potential 
Self-emulsification ability of SMEDDS is directly correlated to 
the spontaneous formation of microemulsion when comes in 
contact with an aqueous environment. Very low self-
emulsification time of SMEDDS formulations favours 
spontaneous emulsification upon the dilution with aqueous 
media. Self-emulsification time of optimized SMEDDS of 
Linagliptin was found to be 10 ± 2 s in phosphate buffer (pH 
6.8) suggests the faster rate of self-emulsification of the 
preconcentrates. It is an index for determination of 
emulsification proficiency to get homogeneous 
microemulsion and would be beneficial for the quick and 
better therapeutic effect [24].  In addition, the zeta-potential 
of the optimized SMEDDS of Linagliptin was found to be –
22.7 ± 1.2 mv depicts that the formulation was stable with no 
aggregation of globules in the continuous phase. This might 
be due to higher concentration of the non-ionic surfactant 
that may cause better self-emulsification of medium chain 
triglycerides in the formulation fabricating a negatively 
charged interface around the oil droplets, thereby enhancing 
the stability of formulation [25].  
3.1.5.2 Thermodynamic stability  
The results of the thermodynamic stability testing of the 
optimized Linagliptin SMEDDS were shown in table 6. 
  
Table 6: Thermodynamic stability testing of the optimized Linagliptin SMEDDS 
Sr. No. Test Observations  
1 Heating cooling cycle Remain Clear without any sign of turbidity 
2 Centrifugation test No phase separation was found 
3 Freeze thaw testing Formulation did not show any precipitation, color change or turbidity 
 
As can see from the table 6, the formulation was 
thermodynamically stable. In brief, heating cooling cycles of 
the SMEDDS exerts stress on the two different phases of the 
microemulsion. Heating may cause coalescence of the oil 
globules by deactivating the surfactant and also cause 
density differrnce between the conituous and dispersed 
phases which may often leads to cracking of microemulsion. 
Moreover, centrifugation provides force that may acts on the 
dispersed phase based on the density difference between 
two phases and leads to coalescence of the oil globules when 
repellent forces were govern by the centrifugal force. Also, 
the freeze thaw stress testing imparts possible stress since 
both of the phases behaves contrarily during the freez thaw 
process with respect to their freezing point.      
3.1.5.3 Cloud point measurement  
Cloud point measurement is further important to determine 
the storage stability of the SMEDDS formulation. The cloud 
point is the temperature above which dehydration of 
SMEDDS components occurs and the clear dispersion may 
become a cloudy one which further affect on the absorption 
of drug through the GIT [26]. Thus, the cloud point of SMEDDS 
formulation should be above the body tmeperature i.e. > 
37°C ). In this investigation, the cloud point value as mean ± 
SD (n=3) of the optimized Solid-SMEDDS formulation was 
found to be 69.0 ± 0.49 °C, indicates the stability of the 
formulation at physiologic temperature. 
3.1.5.4 Transmission Electron Microscopy  
TEM images of diluted SMEDDS is shown in Figure-7. The 
globule size was found to be around 50 nm, having size 
distribution similar to the results obtained by DLS technique.  
 
Figure-7: TEM images of optimized solid-SMEEDS of 
Linagliptin 
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3.1.5.5 Assay 
The drug content i.e. concentration of Linagliptin in the 
optimized solid-SMEDDS was found to be 99.1 ± 0.3 % (9.91 
± 0.4 mg) (n=3).  
3.1.5.6 In-vitrro drug release study 
 The release profile of drug suspension and Linagliptin loded 
solid-SMEDDS is shown in Figure-8. Significantly higher drug 
release (95.6 ± 2.1) of Linagliptin from the Soild-SMEDDS 
than form the drug suspension (28.2 ± 2.3) after 12 h may be 
because of the smaller globule size and increase 
concentration of drug in dissolved form. Moreover, higher 
surface curvature due to the reduction in globule size may 
also leads to immediate/faster solublization of drug at 
oil/water interface. In addition, this rapid release of the drug 
favors higher systemic drug availability due to better 
absorption and bioavailability. As can see from the table 7, 
Linagliptin loaded solid-SMEDDS was follows Korsmeyer 
Peppas model (R2 0.9854, diffudion controlled) whereas the 
value of n (diffusion exponent) was found to [27] be 0.49 
(0.45<n=0.89) i.e. non-fickian transport . 
  
Table 7: Release kinetics of Linagliptin Solid-SMEEDS 
Formulations Linear Regression Coefficient (R2) 
Zero Order 
Model 
First 
Order Model 
Higuchi Model Hixson 
Crowell Model 
Korsmeyer Peppas 
Model 
Drug Suspension 0.9927 0.9989 0.9441 0.9445 0.9833 
Solid-SMEDDS 0.9837 0.8477 0.8663 0.9359 0.9854 
Values are represented as mean (n=3). 
 
Figure 8: In-vitro release profile of drug suspension and 
optimized Linagliptin Soild-SMEDDS 
3.1.5.7 Stability study 
The results of 3 month stability study of Linagliptin Solid-
SMEDDS are represented in Figure-9. The study was 
performed in triplicates and results are expressed as mean ± 
SD. The data suggests that the solid-SMEDDS was 
thermodynamically stable i.e. not significant difference in the 
globule size and assay of the formulation at least for 3 
months. Moreover, the physical appearance of the Solid-
SMEDDS was remained unchanged during the 3 month 
stability study.  
 
Figure 9: Stability data of Linagliptin Solid-SMEDDS at 
Room temperature and Accelerated conditions 
4. CONCLUSION  
In the present investigation, S-SMEDDS technology was 
chosen here as simple, scalable and cost-effective way to 
improve solubility and dissolution profile of Linagliptin. 
Quality by Design approach was utilized for the development 
and optimization of Linagliptin SMEDDS where oil, 
surfactant and co-surfactant were identified as independent 
parameters and globule size and % transmittance were 
selected as response variables. In addition, as a part of the 
control strategy, D-Optimal Mixture design was applied to 
meticulously understand the intricate interfacial phenomena 
among these factors to form SMEDDS. Moreover, 
experimental design was further validated by using check 
point batch analysis and the optimal concentrations of the 
variables were obtained from the design expert software 
within the developed design space. In-vitro characterization 
demonstrated the thermodynamic stability of developed 
SMEDDS along with the significantly enhanced drug release 
profile of the Linagliptin from the formulation. Further, 
developed solid-SMEDDS also exhibits free flowing 
properties and desired self-emulsification potential along 
with the good stability profile over the 3 months. In a 
nutshell, present investigation judiciously extrapolated the 
variegated characteristics of SMEDDS for improving the 
solubility and dissolution profile of poorly soluble anti-
diabetic drug Linagliptin.  
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